Evidence map›Paper›PMID 33461570›Full record

ArticleLipids in health and disease2021

Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis.

Susanne Feder, Reiner Wiest, Thomas S Weiss, Charalampos Aslanidis, Doris Schacherer, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler

Open access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Susanne FederDepartment of Internal Medicine I, Regensburg University Hospital, D-93042, Regensburg, Germany.
Reiner WiestDepartment of Visceral Surgery and Medicine, University Inselspital, Bern, Switzerland.
Thomas S WeissChildren's University Hospital (KUNO), Regensburg University Hospital, Regensburg, Germany.
Charalampos AslanidisInstitute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, Regensburg, Germany.
Doris SchachererDepartment of Internal Medicine I, Regensburg University Hospital, D-93042, Regensburg, Germany.
Sabrina KrautbauerInstitute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, Regensburg, Germany.
Gerhard LiebischInstitute of Clinical Chemistry and Laboratory Medicine, Regensburg University Hospital, Regensburg, Germany.
Christa BuechlerDepartment of Internal Medicine I, Regensburg University Hospital, D-93042, Regensburg, Germany. christa.buechler@klinik.uni-regensburg.de.ORCID http://orcid.org/0000-0002-5635-3994
University Hospital Regensburg · DEUniversity Hospital of Bern · CH

Funding

Deutsche Forschungsgemeinschaft BU 1141/13-1
6 · The paper itself

Abstract

backgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is of particular importance in cholesterol metabolism with high levels contributing to hypercholesterolemia. Cholesterol and sphingolipids are low in patients with liver cirrhosis. Purpose of this study was to find associations of plasma PCSK9 with circulating cholesterol and sphingolipid species and measures of liver disease severity in patients with liver cirrhosis.

methodsPCSK9 protein levels were determined by ELISA in systemic vein (SVP), hepatic vein (HVP) and portal vein plasma of patients with mostly alcoholic liver cirrhosis. PCSK9 and LDL-receptor protein expression were analysed in cirrhotic and non-cirrhotic liver tissues.

resultsSerum PCSK9 was reduced in patients with liver cirrhosis in comparison to non-cirrhotic patients. In liver cirrhosis, plasma PCSK9 was not correlated with Child-Pugh score, Model for End-Stage Liver Disease score, bilirubin or aminotransferases. A negative association of SVP PCSK9 with albumin existed. PCSK9 protein in the liver did not change with fibrosis stage and was even positively correlated with LDL-receptor protein levels. Ascites volume and variceal size were not related to PCSK9 levels. Along the same line, transjugular intrahepatic shunt to lower portal pressure did not affect PCSK9 concentrations in the three blood compartments. Serum cholesterol, sphingomyelin and ceramide levels did not correlate with PCSK9. Stratifying patients by high versus low PCSK9 levels using the median as cut-off, several cholesteryl ester species were even low in the subgroup with high PCSK9 levels. A few sphingomyelin species were also reduced in the patients with PCSK9 levels above the median. PCSK9 is highly expressed in the liver but systemic, portal and hepatic vein levels were similar. PCSK9 was not correlated with the inflammatory proteins C-reactive protein, IL-6, galectin-3, resistin or pentraxin 3. Of note, HVP PCSK9 was positively associated with HVP chemerin and negatively with HVP adiponectin levels.

conclusionsIn the cohort of patients with liver cirrhosis mostly secondary to alcohol consumption high PCSK9 was associated with low levels of certain cholesteryl ester and sphingomyelin species. Positive correlations of PCSK9 and LDL-receptor protein in the liver of patients with chronic liver injury are consistent with these findings.

Indexed as

Severity of Illness IndexAdipokinesAdultAgedAged, 80 and overBiomarkersCholesterolCholesterol, LDLChronic DiseaseCohort StudiesFemaleHumansInflammation MediatorsKidneyLiverLiver CirrhosisAdipokinesBiomarkersCholesterolCholesterol, LDLInflammation MediatorsProprotein Convertase 9Receptors, LDLSphingolipidsSphingomyelinsAlcoholicAscitesCeramideChemerinHepatitis CModel for end-stage liver disease scoreSphingomyelinVarices

Identifiers

PMID33461570
PMCPMC7814535
OpenAlexW3124593295

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.